Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection.
Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Billingsley JM, DePasquale MP, D'Aquila RT, Wolinsky SM, Crawford JM, Montefiori DC, Walker BD. Hay CM, et al. Among authors: billingsley jm. J Virol. 1999 Jul;73(7):5509-19. doi: 10.1128/JVI.73.7.5509-5519.1999. J Virol. 1999. PMID: 10364299 Free PMC article.
Reduced Chronic Lymphocyte Activation following Interferon Alpha Blockade during the Acute Phase of Simian Immunodeficiency Virus Infection in Rhesus Macaques.
Carnathan D, Lawson B, Yu J, Patel K, Billingsley JM, Tharp GK, Delmas OM, Dawoud R, Wilkinson P, Nicolette C, Cameron MJ, Sekaly RP, Bosinger SE, Silvestri G, Vanderford TH. Carnathan D, et al. Among authors: billingsley jm. J Virol. 2018 Apr 13;92(9):e01760-17. doi: 10.1128/JVI.01760-17. Print 2018 May 1. J Virol. 2018. PMID: 29467313 Free PMC article.
Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.
Palesch D, Bosinger SE, Mavigner M, Billingsley JM, Mattingly C, Carnathan DG, Paiardini M, Chahroudi A, Vanderford TH, Silvestri G. Palesch D, et al. Among authors: billingsley jm. J Virol. 2018 Jun 29;92(14):e00279-18. doi: 10.1128/JVI.00279-18. Print 2018 Jul 15. J Virol. 2018. PMID: 29720521 Free PMC article.
Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.
Nganou-Makamdop K, Billingsley JM, Yaffe Z, O'Connor G, Tharp GK, Ransier A, Laboune F, Matus-Nicodemos R, Lerner A, Gharu L, Robertson JM, Ford ML, Schlapschy M, Kuhn N, Lensch A, Lifson J, Nason M, Skerra A, Schreiber G, Bosinger SE, Douek DC. Nganou-Makamdop K, et al. Among authors: billingsley jm. PLoS Pathog. 2018 Aug 24;14(8):e1007246. doi: 10.1371/journal.ppat.1007246. eCollection 2018 Aug. PLoS Pathog. 2018. PMID: 30142226 Free PMC article.
Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.
Stanley TL, Fourman LT, Wong LP, Sadreyev R, Billingsley JM, Feldpausch MN, Zheng I, Pan CS, Boutin A, Lee H, Corey KE, Torriani M, Kleiner DE, Chung RT, Hadigan CM, Grinspoon SK. Stanley TL, et al. Among authors: billingsley jm. Clin Infect Dis. 2021 Aug 16;73(4):621-630. doi: 10.1093/cid/ciab019. Clin Infect Dis. 2021. PMID: 33852720 Free PMC article. Clinical Trial.
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Fourman LT, et al. Among authors: billingsley jm. JCI Insight. 2020 Aug 20;5(16):e140134. doi: 10.1172/jci.insight.140134. JCI Insight. 2020. PMID: 32701508 Free PMC article. Clinical Trial.
40 results